Cogent Biosciences, INC Form 4 insider transactions

Cogent Biosciences' CEO, Andrew R. Robbins, was granted 915,000 stock options on January 23, 2025, which vest over four years.

Cogent Biosciences' Chief Legal Officer, Evan Kearns, was granted 230,000 stock options on January 23, 2025, which vest over four years.

Cogent Biosciences' Chief Commercial Officer, Cole Pinnow, acquired 43,750 shares of common stock at an average price of $7.598 per share on January 14, 2025.

Director Karen Jean Ferrante acquired 2,785 stock options in Cogent Biosciences in lieu of cash compensation, according to a recent SEC filing.

Director Karen Jean Ferrante acquired 2,034 stock options in Cogent Biosciences in lieu of cash compensation on October 1, 2024.

Director Karen Jean Ferrante acquired 2,462 shares of Cogent Biosciences through a stock option award in lieu of cash compensation.

Christopher W. Cain, a director of Cogent Biosciences, Inc., acquired stock options for 44,700 shares of common stock on June 5, 2024.

Director Matthew Ros acquired 44,700 stock options in Cogent Biosciences, Inc. on June 5, 2024.

Karen Jean Ferrante, a director of Cogent Biosciences, acquired 44,700 stock options on June 5, 2024.

Director Peter Evan Harwin acquired 44,700 stock options in Cogent Biosciences, Inc. under an arrangement with Fairmount Funds Management LLC.

Director Todd Shegog acquired stock options in Cogent Biosciences, Inc. on June 5, 2024.

Director Arlene Morris acquired 44,700 stock options in Cogent Biosciences, Inc. on June 5, 2024.

Fairmount Funds Management LLC converted 1,500 shares of Series B Convertible Preferred Stock into 1,500,000 shares of Common Stock of Cogent Biosciences after the company's stockholders approved an amendment to increase the number of authorized shares.

Cole Pinnow, Chief Commercial Officer of Cogent Biosciences, acquired 525,000 stock options on May 25, 2024, according to a Form 4 filing.

Director Karen Jean Ferrante acquired 3,213 stock options in Cogent Biosciences in lieu of cash compensation on April 1, 2024.

Fairmount Funds Management LLC reports the transfer of Cogent Biosciences common stock and Series A convertible preferred stock from Fairmount Healthcare Fund LP to Fairmount Healthcare Fund II LP due to the wind down of the former.